3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
74
Colonic Neoplasms
31
Rectal Neoplasms
29
Neoplasm Metastasis
16
Stomach Neoplasms
12
Pancreatic Neoplasms
12
Esophageal Squamous Cell Carcinoma
8
Small Cell Lung Carcinoma
7
Neoplasms
6
Esophageal Neoplasms
6
Rhabdomyosarcoma
4
Intestinal Neoplasms
4
Gastrointestinal Neoplasms
4
Digestive System Neoplasms
4
Uterine Cervical Neoplasms
3
Sarcoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Cholangiocarcinoma
3
Biliary Tract Neoplasms
3
Rectal Diseases
2
Neuroblastoma
2
Neoplasms by Histologic Type
2
Intestinal Diseases
2
Hepatoblastoma
2
Gastrointestinal Diseases
2
Ganglioneuroblastoma
2
Digestive System Diseases
2
Colorectal Cancer Metastatic
2
Colorectal Adenocarcinoma
2
Colonic Diseases
2
Interventions
osimertinib
1
obinutuzumab
1
midostaurin
1
flumatinib
1
fludarabine
1
Radiotherapy
1
Oxaliplatin
1
Mitoxantrone
1
Mercaptopurine
1
Leucovorin
1
Irinotecan
1
Gemtuzumab
1
Folfox protocol
1
Fluorouracil
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm, Residual
×
Irinotecan
×
Clear all
NCT05427669
2022-10-07
AFFORD
Sun Yat-sen University
Phase 3
Not yet recruiting
340 enrolled